硫酸氢氯吡格雷(Clopidogrel Bisulfate) - 药物靶点：P2Y12 receptor_在研适应症：动脉粥样硬化，稳定型心绞痛，脑血管疾病_专利_临床

概要

基本信息

简介Clopidogrel Bisulfate 是一种商标为 Plavix® 的药物，在1997年于美国批准上市，由施贵宝研发。其作用机制是抑制P2Y12受体，从而减少血小板活化和聚集。这随后降低了血栓的风险及其潜在的致命后果。氯吡格雷适用于治疗心肌梗塞、中风、外周血管疾病、冠状动脉疾病和脑血管疾病。由于其作为抗血小板药物的作用，氯吡格雷被证明在预防血栓引起的严重并发症（如心脏病发作、中风甚至死亡）方面具有无可估量的价值。该药物在心血管事件的管理和预防方面显示出疗效，使其成为现代医学的基本药物。

药物类型

小分子化药

别名

clopidogrel、Clopidogrel Bisufate、Clopidogrel bisulfate (USP)

+ [28]

靶点

P2Y12 receptor

作用机制

P2Y12 receptor拮抗剂(嘌呤P2Y12受体拮抗剂)

治疗领域

神经系统疾病心血管疾病

在研适应症

动脉粥样硬化稳定型心绞痛脑血管疾病+ [14]

非在研适应症

冠心病心脏停搏先天性心脏缺损+ [4]

原研机构

Bristol Myers Squibb Co.

在研机构

Zentiva ksTaw Pharma (Ireland) Ltd.

Viatris, Inc.

+ [10]

非在研机构

Sanofi SA

Bristol Myers Squibb Co.Mylan dura GmbH

+ [7]

最高研发阶段批准上市

首次获批日期

美国 (1997-11-17),

心肌梗塞脑卒中

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构

分子式C16H18ClNO6S2

InChIKeyFDEODCTUSIWGLK-RSAXXLAASA-N

CAS号120202-66-6

关联

419

项与硫酸氢氯吡格雷相关的临床试验

NCT05643651 / Not yet recruiting临床4期IIT

Rivaroxaban Versus Warfarin for Thromboprophylaxis in Children With Giant Coronary Artery Aneurysms After Kawasaki Disease: a Multicenter, Open-label, Parallel, Exploratory, Randomized Controlled Trial

Based on population pharmacokinetic model-based simulation, a 15 mg-equivalent, age-, and bodyweight-adjusted dosing regimen for Chinese children with giant coronary artery aneurysms after acute Kawasaki disease was proposed. This exploratory trial aims to evaluate the feasibility, safety and effectiveness of rivaroxaban compared to warfarin for thromboprophylaxis in children with giant coronary artery aneurysms after Kawasaki disease

开始日期2024-12-01

申办/合作机构

复旦大学附属儿科医院

NCT06584812 / Active, not recruiting临床1期

A Phase I Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety in Healthy Subjects With Multiple Administration of Tiprogrel

This study is designed to evaluate the pharmacokinetics, pharmacodynamics and safety in healthy subjects with multiple administration of Tiprogrel.

开始日期2024-09-09

申办/合作机构

天津药物研究院有限公司

CTR20242810 / Active, not recruitingN/A

硫酸氢氯吡格雷片人体生物等效性研究

本试验旨在研究单次空腹和餐后口服辽宁鑫善源药业有限公司研制、生产的硫酸氢氯吡格雷片（75 mg）的药代动力学特征；以赛诺菲（杭州）制药有限公司持证、生产的硫酸氢氯吡格雷片（波立维®，75 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。

开始日期2024-08-28

申办/合作机构

辽宁鑫善源药业有限公司

100 项与硫酸氢氯吡格雷相关的临床结果

登录后查看更多信息

100 项与硫酸氢氯吡格雷相关的转化医学

登录后查看更多信息

100 项与硫酸氢氯吡格雷相关的专利（医药）

登录后查看更多信息

2,046

项与硫酸氢氯吡格雷相关的文献（医药）

2025-01-01·AMERICAN HEART JOURNAL

Dual antiplatelet therapy duration and stent type in patients with high bleeding risk: A systematic review and network meta-analysis

Article

作者: Hosseini, Kaveh ; Takagi, Hisato ; Wiley, Jose ; Saito, Tetsuya ; Kuno, Toshiki ; Gupta, Rahul ; Bangalore, Sripal ; Fujisaki, Tomohiro

BACKGROUND:

It is uncertain whether the efficacy and safety of dual antiplatelet therapy (DAPT) in patients with high bleeding risk (HBR) vary according to DAPT duration and stent type (eg, durable polymer drug-eluting stents (DP-DESs), biodegradable polymer DESs (BP-DESs), or polymer-free drug-coated stents (PF-DCSs)). We aimed to study the stent type and DAPT duration appropriate for patients with HBR.

METHODS:

PubMed and EMBASE were searched until October 2023. Randomized controlled trials (RCTs) involving patients with HBR that compared standard DAPT (6-12 months) with DP- or BP-DES versus short DAPT (≤3 months) with DP- or BP-DES or PF-DCS or bare-metal stent (BMS) were identified. The primary efficacy outcome was major adverse cardiovascular events (MACEs), defined as cardiovascular death, myocardial infarction (MI), and stroke. The primary safety outcome was major bleeding. Secondary outcomes included MI and stent thrombosis (ST). We performed a network meta-analysis using a random effects model.

RESULTS:

Thirteen RCTs with a total of 19,418 patients with HBR were included. Compared to standard DAPT with DP-DES, short DAPT with BMS was associated with a higher risk of MACE and MI. For major bleeding, short DAPT strategies were associated with a lower risk than standard DAPT strategies (e.g. short DAPT with DP-DES vs standard DAPT with DP-DES; HR[95% CI]: 0.48[0.28-0.82]). Interestingly, the use of BP-DES was associated with a higher risk of ST than DP-DES (e.g. standard DAPT with BP-DES vs short DAPT with DP-DES; HR[95% CI]: 2.65[1.03-6.79]).

CONCLUSIONS:

In patients with HBR who underwent percutaneous coronary intervention, a short DAPT strategy with DP-DES should be used since it offers the best combination of efficacy and safety.

2024-12-01·INTERNATIONAL DENTAL JOURNAL

Hydrated Calcium Silicate in Resin Composites for Prevention of Secondary Caries

Article

作者: Han, A Ruem ; Kim, Dohyun ; Kim, Kwang-Mahn ; Kwon, Jae-Sung ; Yang, Song-Yi

INTRODUCTION AND AIMS:

The gaps at the margins of restorative composite resin can increase as the carious process occurs underneath the materials, causing further demineralization along the tooth cavity wall. The aim of this study was to evaluate the effects of restorative resin composite containing hydrated calcium silicate (hCS) filler on enamel protection against demineralization by simulating microleakage between the test material and teeth in a cariogenic environment.

METHODS:

The experimental resin composites were composed of 70 wt.% filler, which was mixed with a glass filler and hCS in a weight ratio of 70.0% glass (hCS 0), 17.5% hCS + 52.5% glass (hCS 17.5), 35.0% hCS + 35.0% glass (hCS 35.0), and 52.5% hCS + 17.5% glass (hCS 52.5). A light-cured experimental resin composite disk was positioned over a polished bovine enamel disk, separated by a 30-µm gap, and immersed in artificial saliva with pH 4.0 for 15, 30, and 60 days. After the immersion period, the enamel disk was separated from the resin composite disk and evaluated using a microhardness tester, atomic force microscopy, and polarized light microscopy. The opposing sides of the enamel and resin composite disks were observed using scanning electron microscopy/energy dispersive X-ray spectrometry.

RESULTS:

The enamel surface showed a significant increase in microhardness, decreased roughness, and remineralization layer as the proportion of hCS increased (P < .05). In the scanning electron microscopy image, the enamel surface with hCS 35.0 and 52.5 after all experimental immersion periods, showed a pattern similar to that of a sound tooth.

CONCLUSIONS:

The results demonstrated that increasing the hCS filler level of restorative resin composites significantly decreased enamel demineralization.

CLINICAL RELEVANCE:

Hydrated calcium silicate laced restorative resin composites may be a promising dental biomaterial for protecting teeth against demineralization and preventing secondary caries around restorations.

2024-12-01·POULTRY SCIENCE

The interactivity of sources and dietary levels of resistant starches – impact on growth performance, starch, and nutrient digestibility, digesta oligosaccharides profile, cecal microbial metabolites, and indicators of gut health in broiler chickens

Article

作者: Olukosi, Oluyinka A. ; Oluseyifunmi, Iyabo W ; Lourenco, Jeferson ; Olukosi, Oluyinka A ; Oluseyifunmi, Iyabo W.

In a 21-d study, 480 Cobb 500 (off-sex) male broiler chicks were used to investigate the effects of feeding different sources and levels of resistant starches (RS) on growth performance, nutrient and energy utilization, and intestinal health in broiler chickens. The birds were allocated to 10 dietary treatments in a 3 × 3 + 1 factorial arrangement. The factors were 3 RS-sources (RSS): banana starch (BS), raw potato starch (RPS), and high-amylose corn starch (HCS); each at 3 levels (RSL) 25, 50, or 100 g/kg plus a corn-soybean meal control diet. Birds and feed were weighed on d 0, 8, and 21. On d 21, samples of jejunal tissue and digesta were collected for chemical analysis. Data were analyzed using the mixed model procedure of JMP with factor levels nested with the control. In the 0 to 21 phase, the birds fed the RPS diets had higher (P = 0.011) FI than those fed HCS or control diets, and FCR was greater (P = 0.030) in birds that received BS diets than in other diets. RSS × RSL was significant (P < 0.05) for total tract nutrient retention, AME, and AMEn on d 21. The starch digestibility was higher (P < 0.001) in birds that received the control diet than in RS diets, and decreased as RS levels increased, except for HCS. The apparent metabolizable energy (AME) and nitrogen-corrected AME (AMEn) were higher (P < 0.001) in birds fed 100 g/kg HCS diet, with both decreasing with increasing levels of BS and RPS, except for HCS. Relative ileal oligosaccharides profile showed significant (P < 0.05) RSS × RSL with a higher relative abundance of Hex(3) (P = 0.01) and Pent(3) (P = 0.001) in HCS diets. In conclusion, RS may influence gut health and growth performance in broiler chickens through modulation of cecal SCFA and nutrient digestion, but these depend largely on the botanical origin and concentrations of individual RS.

270

项与硫酸氢氯吡格雷相关的新闻（医药）

2024-11-15

·Pharma CMC

刚刚，石药集团前三季度业绩公布！营收226.86亿

今日（11月15日），石药集团公布2024年前三季度业绩，报告期内，收入为人民币226.86亿元，较去年同期下跌4.9%。主要受到成药业务收入下跌的影响，股东应占基本溢利39.99亿元，较去年同期下跌15.2%，股东应占溢利较去年同期下跌15.9%至人民币37.78亿元。据公告披露，石药集团成药业务收入为人民币186.70亿元，同比下降3.5%，以下为按主要治疗领域的销售情况：神经系统治疗领域于第三季度的收入较去年同季下跌15.8%，然而，与去年同期（前三季度）相比，本期该领域的收入取得整体增长4.5%。恩必普（®丁苯酞软胶囊、丁苯酞氯化钠注射液）主要因医院在严格控制医疗费用的环境下，对在医院用量排名靠前的药品实施较严格的管控，使其本年第三季度销售有较大幅度的下跌。另一方面，明复乐®（注射用重组人TNK组织型纤溶酶原激活剂）用于治疗急性缺血性卒中患者的新适应症于年初获得上市批准后，于本期取得理想的销售收入。抗肿瘤治疗领域于第三季度和本期的收入分别较去年同季和同期下跌31.2%和17.6%。下跌主要由于津优力（®聚乙二醇化重组人粒细胞刺激因子注射液）及多美素（®盐酸多柔比星脂质体注射液）两款产品的价格于京津冀「3+N」联盟药品集中采购中分别下调了约58%和23%。新产品方面，多恩益（®盐酸伊立替康脂质体注射液）、多恩达（®盐酸米托蒽醌脂质体注射液）及戈瑞特（®甲磺酸仑伐替尼胶囊）的销售于期内仍保持较高增长。心血管治疗领域于第三季度和本期的收入分别较去年同季和同期下跌26.7%和11.1%。下跌主要由于玄宁®（马来酸左氨氯地平片及分散片）并没有在2023年的国家第八批集中采购中中选，使其在严格执行集采政策的医院的销售受到较大冲击，尤其本年第二季度及第三季度的跌幅较为显着。另外，恩存®（硫酸氢氯吡格雷片）及意舒宁®（硝苯地平控释片）于期内的销售保持增长。呼吸系统治疗领域于第三季度和本期的收入分别较去年同季和同期下跌35.1%和18.8%。期内琦效（®盐酸阿比多尔片）的销售收入因市场需求减少而有较大幅度的下跌。另外，受惠于有效的推广策略及强劲的市场需求，伊络达®（乙磺酸尼达尼布软胶囊）及诺一安®（孟鲁司特钠片╱咀嚼片）的销售收入于期内保持理想增长。消化代谢治疗领域于第三季度的收入较去年同季下跌11.2%，然而，与去年同期相比，本期该领域的收入大幅增长30.7%。其中，欧倍妥®（艾司奥美拉唑镁肠溶胶囊）及得必欣®（奥美拉唑肠溶胶囊╱片╱注射剂）受惠于有效的推广策略及市场需求，增长尤其显着。 2024年前三季度，石药集团研发费用为人民币38.80亿元，较去年同期增加5.5%，约占成药业务收入20.8%。目前逾60个重点在研药物已进入临床或申报阶段，其中6个已递交上市申请，24个产品（30个适应症）处于注册临床阶段。自年初至今，于中国有2款创新药（新增适应症）、1款生物类似药、1款特殊制剂获批上市，及在研药物获得34项临床试验批件，7款仿制药获得药品注册批件；于北美地区有3款在研创新药物获得临床试验批准，1项快速通道资格认定。临床管线概览：

财报带量采购临床3期申请上市孤儿药

2024-11-13

·精准药物

销售额超40亿的化药品种，你绝对想不到

化药在医疗领域扮演着至关重要的角色，化药品种的销售额表现如何？药智数据显示，2023年化药市场总销售额超过7400亿元，销售额同比增长0.42%，包含2483个企业的4255个品种，平均每个品种约1.74亿元销售额。具体来看，2023年化药销售额超40亿的大品种数量有7个，总销售额达478亿元，约占化药整体市场份额的6%。其中，2023年国内公立医疗机构化药品种最高销售额为183.12亿元；销售额50亿元-60亿元的2款，40亿元左右品种4款。注：本文仅讨论2023年国内公立医疗机构化药品种销售额，数据仅供参考，如有疏漏敬请指正。 >01< 7个化药品种，销售额超40亿中国的化学制药行业已经成为全球第二大药品市场，规模以上化学原料药和制剂生产企业数量众多，显示了化学药品在全球药品市场中的重要地位。最高销售额183.12亿元。从销售额来看，2023年国内公立医疗机构销售额超40亿的化药大品种有7个，分别是氯化钠注射液、阿托伐他汀钙片、葡萄糖注射液、硫酸氢氯吡格雷片、注射用头孢哌酮钠舒巴坦钠(2:1)、他克莫司胶囊、丁苯酞氯化钠注射液（销售额见下图1）。4款品种销售额在40亿元左右，2款在50亿元-60亿元，最高氯化钠注射液达到183.12亿元。图1 2023年销售额超40亿的化药大品种（7款）图片来源：药智数据氯化钠注射液“一枝独秀”。从销售额超40亿的化药大品种TOP榜来看，氯化钠注射液的2023年国内公立医疗机构销售额可谓“一枝独秀”，不仅突破百亿，而且成为榜上唯一突破150亿元的品种。药智数据显示，2016年以来，氯化钠注射液的国内公立医疗机构年销售额均超100亿元，近8年销售额突破1200亿元大关。企业排行“二龙争霸”。从2023年企业化药销售额TOP10来看，则有很大不同。辉瑞与阿斯利康超过200亿元，位列前两位且差距较小，两者竞争格局或将在2024年有所改变：榜上龙头老大辉瑞，手握年销售额超20亿元大将5个，阿托伐他汀钙片更是年销超50亿元，未来可期。第二名阿斯利康也“不甘示弱”，以3个超30亿元+5个超10亿元大品种紧追不舍，誓要在2024年迎头赶上。图2 2023年企业化药销售额TOP10 图片来源：药智数据第二梯队来看，年销售额超过百亿（低于200亿）的企业有江苏恒瑞医药、拜耳、诺华、正大天晴、齐鲁制药5家企业，本土药企占据3席。就2023年化药ATC分类销售额来看，系统用抗感染药、血液和造血器官药物、消化道及代谢药物“三足鼎立”，心血管系统用药及抗肿瘤和免疫机能调节药与前三名差距不大，分布较为均衡。图3 2023年化药ATC分类销售额图片来源：药智数据随着人们对健康的重视程度不断提高，不同适应症的药品需求量增加，促进了化学制药行业的发展。特别是在仿制药一致性评价和带量采购政策双重推动下，化学药品制剂行业集中度进一步提高，这可能使得不同适应症的药品在市场上的竞争力更加均衡，导致了化药适应症销售额较为平均的局面。 >02< 化药销售额TOP3 药智数据显示，2023年化药销售额TOP100中，其销售额“门槛”为13.2亿，超过30亿的品种有20款、占比20%，低于30亿元品种有80款，占比80%。总体来看，化药销售额TOP100品种的销售额较高，均超过10亿元，这是生物药（2.41亿）、中药（4.9亿）暂时无法企及的。 TOP3品种来看，氯化钠注射液、阿托伐他汀钙片、葡萄糖注射液占据前三。图4 2023年化药销售额TOP10 图片来源：药智数据 1. 氯化钠注射液 2023年，氯化钠注射液总销售额183.12亿元，成为当年的化药“销冠”，由122家企业瓜分市场，其中四川科伦药业、石家庄四药、山东齐都药业位列前三，销售额分别为32.82亿元、18.13亿元、15.99亿元。氯化钠注射液是临床最常用的电解质溶液之一，主要用于维持人体水电解质平衡。它被广泛用于补充体液、维持电解质平衡、稀释药物、冲洗伤口和用于透析等多种医疗场景。中国被称为输液大国，大输液在中国的临床应用极为广泛，是医疗机构使用最普遍的药品制剂之一。药智数据显示，2016年—2023年，氯化钠注射液的国内公立医疗机构销售额已高达1263.47亿元，年销售额均在100亿元以上。图5 2016年—2023年，氯化钠注射液国内公立医疗机构销售额图片来源：药智数据 2. 阿托伐他汀钙片 2023年，阿托伐他汀钙片总销售额62.58亿元，成为当年的化药销售额第二名，由18家企业瓜分市场，其中辉瑞独占鳌头，2023年销售额达51.87亿元，占当年市场总量62.58亿元的83%。药智数据显示，2016年—2023年，阿托伐他汀钙片的国内公立医疗机构销售额为592.36亿元，于集采中标后市场逐渐缩小。图6 2016年—2023年，阿托伐他汀钙片国内公立医疗机构销售额图片来源：药智数据 3. 葡萄糖注射液 2023年，葡萄糖注射液总销售额54.72亿元，成为当年化药销售额第三名。葡萄糖注射液是一种基本的静脉营养补充剂，作为基础输液的一种，它被广泛用于补充能量、维持血糖水平、稀释药物等多种医疗场景。药智数据显示，2016年—2023年，葡萄糖注射液的国内公立医疗机构销售额达480.29亿元，年销售额常年保持在50亿元以上。图7 2016年—2023年，葡萄糖注射液国内公立医疗机构销售额图片来源：药智数据 >03< 7款正增长，最高增速94% 2023年化药销售额TOP10中，7款药物实现同比正增长，包括硫酸氢氯吡格雷片、他克莫司胶囊等品种。值得注意的是，氯化钠注射液、丁苯酞氯化钠注射液在激烈的竞争形势下，2023年保持排名不变。表1 2023年化药销售额TOP10（单位：亿元）数据来源：药智数据上表可见，2023年化药销售额最高增长率94%，为注射用头孢哌酮钠舒巴坦钠(2:1)，排名也同比上升37位、居第五位，从20亿元量级突破40亿元，增速惊人。注射用头孢哌酮钠舒巴坦钠可谓抗感染药领域的“顶流”，其中注射用头孢哌酮钠舒巴坦钠(2:1)的年销售额早已在2019年国内公立医疗机构销售额突破30亿元大关，并于2023年突破40亿元。注射用头孢哌酮钠舒巴坦钠是一种高效抗感染复方制剂，适用于敏感菌引发的多部位感染，其广泛的应用范围和良好的疗效，市场需求较大。增速第二的是布地奈德雾化吸入混悬液，销售额同比增长29%。该品种由5个企业占据市场，其中阿斯利康为榜上唯一年销售额破10亿元的企业，达17.48亿元；正大天晴为9.29亿元，有望在今年突破10亿元。增速第三名为硫酸氢氯吡格雷片，同比增速12%。该品种虽然由13个企业瓜分市场，但赛诺菲一家独占25.68亿元，占据总市场份额的52%，本土药企信立泰药业紧随其后，以9.1亿元年销售额排名第二，石药欧意及乐普药业年销售额均超过5亿元。其他企业年销售额均在1亿元以下。 >04< 结语总体来看，2023年化药销售额TOP榜中，销售额靠前药品市场由多家药企瓜分，但份额差距较大，出现“赢家通吃”效应，即头部企业独占大部分市场份额，留给其他药企的利益空间越来越小。反观生物药、中药的销售额TOP榜，通常为独家品种名列前茅，可见差异化竞争将是未来市场发展的重要趋势。参考来源： 1、药智数据 2、https://www.huaon.com/channel/trend/943533.html 3、《中国氯化钠注射液行业研究与市场前景分析报告》，中国产业调研网声明：发表/转载本文仅仅是出于传播信息的需要，并不意味着代表本公众号观点或证实其内容的真实性。据此内容作出的任何判断，后果自负。若有侵权，告知必删！长按关注本公众号粉丝群/投稿/授权/广告等请联系公众号助手觉得本文好看，请点这里↓

IPO申请上市医药出海

2024-11-13

·PRNewswire

Helix Debuts Novel Precision Effectiveness Model That Predicts 12-Month Weight Loss Response of Semaglutide in Diverse Populations

Research presented in suite of data from the company at the American Society of Human Genetics (ASHG) 2024 Annual Meeting demonstrates broad capabilities of the Helix Research Network, the largest and fastest growing precision clinical research network SAN MATEO, Calif., Nov. 13, 2024 /PRNewswire/ -- Helix, a leader in population genomics and precision health, unveiled new clinical research at the ASHG 2024 Annual Meeting, featuring a novel precision effectiveness model that predicts the 12-month weight loss response of semaglutide in diverse populations. Researchers at Helix found that an integrated polygenic risk score with co-morbid factors such as the presence of type 2 diabetes and hypertension could predict the 12 month weight loss response to semaglutide treatment in individuals. Among 2.4mg semaglutide users, those in the fifth/top quintile of the newly developed score (after correcting for sex and genetic similarity) were ~ 2x more likely to achieve 10% weight loss than those in the first/bottom quintile. "This model has the potential to deliver on the promise of transforming precision medicine for patients being treated with semaglutide," said Matthew Levy, Ph.D., senior research scientist at Helix. "By providing dosage-specific weight loss expectations and predicting which patients are most likely to respond, we can help ensure that each patient receives the most appropriate treatment from the start." Helix's precision effectiveness model for semaglutide could be used for patients and providers to: Identify individuals most likely to respond to treatment Improve shared decision making around the best individual treatment for obesity Provide estimates of expected weight loss over time, or the likelihood of response Guide dosage considerations to help balance weight loss goals with possible side effects This research was made possible by data collected from the Helix Research Network (HRN), the largest and fastest-growing precision clinical research network designed to advance science and health insights. The growing network comprises leading health systems across North America, including the Medical University of South Carolina, HealthPartners, Renown Health, and more. With its rich data, life science researchers can conduct innovative studies in a wide range of therapeutic areas including cardiometabolic diseases, neurodegenerative conditions, autoimmune disorders, and more to drive drug discovery and development. "The Helix Research Network marks a significant leap forward in precision health, allowing us to extract meaningful insights from a comprehensive clinicogenomics dataset from across North America," said William Lee, Ph.D., chief science officer at Helix. "Through our collaboration with our partners, we are generating insights that will shape the future of medicine – guiding more effective, personalized treatments across a range of diseases. We're thrilled to support this breakthrough research that can bring transformative changes for patients worldwide and help redefine healthcare." Additional research presented at ASHG 2024 displaying the breadth and depth of how HRN data can be applied includes: Research that underscores the importance of pharmacogenomic (PGx) testing, or referencing patients' genotype before prescribing medications. In a retrospective study of clopidogrel, a drug that prevents blood clots, it was found that 25% of individuals prescribed this medication had a mismatch between their recommended dosage (based on their genotype) and their prescribed dose. Twelve percent of these mismatched individuals were poor metabolizers, meaning they should not be prescribed clopidogrel at all. In addition, 25% of these poor metabolizers experienced thrombosis (a blood clot) after the initiation of clopidogrel. These adverse outcomes could have been prevented by first undergoing PGx testing to assess metabolism. A study that includes a method to help determine predictors of future risk for cardiovascular disease. Lipoprotein a (Lp(a)) is a useful predictor of cardiovascular disease. However, it can be difficult to obtain consistent and accurate measurements. Helix developed a method for estimating the number of KIV-2 repeats within an exome profile, which can then be used in combination with a genetic risk score to predict Lp(a). This variability is particularly impactful in non-European ancestries, which is significant as past risk score methods have not been effective for diverse populations. Other abstracts and platform talks presented at ASHG highlight the magnitude of the autoimmune population in the Helix Research Network, identify individuals at low risk of disease using genetics, utilize a methodology to group rare coding variants to determine the impact to protein structure and more. To learn more about the studies presented at ASHG, please visit . About Helix: Helix is the leading population genomics and precision health organization. Helix enables health systems, life sciences companies and payers to accelerate the integration of genomic data into patient care and therapeutic development. Learn more at . About the Helix Research Network: The Helix Research Network is Helix's groundbreaking genomics research program, advancing science and health insights. It is the largest and fastest growing precision clinical research network in North America, with over 1 million committed patients. To learn more, visit: . Media Contact: [email protected] SOURCE Helix WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床研究

100 项与硫酸氢氯吡格雷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00769	硫酸氢氯吡格雷	B01AC04	DB00758

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
动脉粥样硬化	欧盟	Pharmathen SA	2009-07-27
动脉粥样硬化	冰岛	Pharmathen SA	2009-07-27
动脉粥样硬化	列支敦士登	Pharmathen SA	2009-07-27
动脉粥样硬化	挪威	Pharmathen SA	2009-07-27
稳定型心绞痛	中国	深圳信立泰药业股份有限公司	2000-01-01
脑血管疾病	中国	深圳信立泰药业股份有限公司	2000-01-01
心肌缺血	中国	深圳信立泰药业股份有限公司	2000-01-01
非ST段抬高型心肌梗死	中国	深圳信立泰药业股份有限公司	2000-01-01
非 ST 段抬高急性冠脉综合征	欧盟	Sanofi Winthrop Industrie SA	1998-07-15
非 ST 段抬高急性冠脉综合征	冰岛	Sanofi Winthrop Industrie SA	1998-07-15
非 ST 段抬高急性冠脉综合征	列支敦士登	Sanofi Winthrop Industrie SA	1998-07-15
非 ST 段抬高急性冠脉综合征	挪威	Sanofi Winthrop Industrie SA	1998-07-15
非q波心肌梗死	欧盟	Sanofi Winthrop Industrie SA	1998-07-15
非q波心肌梗死	冰岛	Sanofi Winthrop Industrie SA	1998-07-15
非q波心肌梗死	列支敦士登	Sanofi Winthrop Industrie SA	1998-07-15
非q波心肌梗死	挪威	Sanofi Winthrop Industrie SA	1998-07-15
ST段抬高心肌梗死	欧盟	Sanofi Winthrop Industrie SA	1998-07-15
ST段抬高心肌梗死	冰岛	Sanofi Winthrop Industrie SA	1998-07-15
ST段抬高心肌梗死	列支敦士登	Sanofi Winthrop Industrie SA	1998-07-15
ST段抬高心肌梗死	挪威	Sanofi Winthrop Industrie SA	1998-07-15

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
先天性心脏缺损	临床3期	美国	Sanofi SA	2009-01-01
先天性心脏缺损	临床3期	美国	Bristol Myers Squibb Co.	2009-01-01
先天性心脏缺损	临床3期	巴西	Sanofi SA	2009-01-01
先天性心脏缺损	临床3期	巴西	Bristol Myers Squibb Co.	2009-01-01
先天性心脏缺损	临床3期	法国	Bristol Myers Squibb Co.	2009-01-01
先天性心脏缺损	临床3期	法国	Sanofi SA	2009-01-01
先天性心脏缺损	临床3期	德国	Sanofi SA	2009-01-01
先天性心脏缺损	临床3期	德国	Bristol Myers Squibb Co.	2009-01-01
先天性心脏缺损	临床3期	匈牙利	Sanofi SA	2009-01-01
先天性心脏缺损	临床3期	匈牙利	Bristol Myers Squibb Co.	2009-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02777580 (STREAM-2, CTgov)	临床4期	心肌梗塞	609	Coronary angiography+clopidogrel+Tenecteplase (Pharmaco-invasive Strategy)	餘遞積襯築膚鏇糧襯鹹(鑰糧艱艱淵選範糧範膚) = 選糧窪鬱襯夢範衊鹽繭衊壓簾壓鹹範壓鹽築積 (鹹製壓艱鹽觸鑰積獵醖, 築鹹繭選鹽選積遞積構 ~ 遞願範醖鏇積願顧蓋鬱) 更多	-	2024-10-04
				Primary PCI (Standard Primary PCI)	餘遞積襯築膚鏇糧襯鹹(鑰糧艱艱淵選範糧範膚) = 範淵壓鹹製積願艱網簾衊壓簾壓鹹範壓鹽築積 (鹹製壓艱鹽觸鑰積獵醖, 遞鬱膚製衊憲顧夢製鑰 ~ 糧範製鹽廠獵齋顧艱顧) 更多
NCT03161678 (CTgov)	临床4期	血栓形成 \| 心肌梗塞 \| 血小板疾病	111	clopidogrel+Ticagrelor (Wild-Type Genotype)	餘糧鹹憲蓋壓襯鬱遞廠(顧簾淵選網齋艱繭簾繭) = 選糧襯衊憲醖餘鬱鹽獵廠觸艱願觸遞觸壓簾繭 (廠艱鹽鬱製齋鏇選壓製, 廠簾構選膚鏇鹽膚淵艱 ~ 鹽糧窪窪鹹鏇範鏇淵築) 更多	-	2024-05-06
				clopidogrel+Ticagrelor (Carriers of the CES1 G143E Mutation)	餘糧鹹憲蓋壓襯鬱遞廠(顧簾淵選網齋艱繭簾繭) = 餘淵願鹹壓鑰艱遞蓋艱廠觸艱願觸遞觸壓簾繭 (廠艱鹽鬱製齋鏇選壓製, 齋觸願鑰顧獵範廠夢網 ~ 願壓鹽餘觸獵觸遞蓋廠) 更多
AAN2024	N/A	颅内动脉瘤	13	Clopidogrel	糧襯醖餘獵壓構夢鏇鹽(蓋積鏇鬱範壓網選夢糧): OR = 1.01 (95% CI, 0.59 ~ 1.73), P-Value = 0.97 更多	积极	2024-04-09
				Ticagrelor
NCT04409834 (COVID-PACT, CTgov)	临床4期	新型冠状病毒感染 \| 动脉血栓形成 \| 静脉血栓栓塞	390	Unfractionated Heparin IV+Clopidogrel+Enoxaparin 1 mg/kg (Full-dose Anticoagulation (FDAC))	窪夢獵鏇鏇遞顧壓顧獵(繭積夢壓鹹網鬱繭齋顧) = 選選獵餘選鏇蓋鹽憲夢鏇壓選製鹹鑰餘襯製鑰 (積襯夢醖製艱膚餘蓋壓, 願顧遞壓網壓膚餘鬱窪 ~ 簾糧網鏇選鬱廠簾窪餘) 更多	-	2024-01-19
				Unfractionated heparin SC+clopidogrel+Enoxaparin 40 mg SC (Standard-dose Prophylactic Anticoagulation (SDPAC))	窪夢獵鏇鏇遞顧壓顧獵(繭積夢壓鹹網鬱繭齋顧) = 鬱餘構窪憲獵廠蓋艱範鏇壓選製鹹鑰餘襯製鑰 (積襯夢醖製艱膚餘蓋壓, 遞簾鬱獵鹽簾選蓋襯觸 ~ 積構遞齋製襯選願襯網) 更多
NCT03774394 (CTgov)	临床4期	2型糖尿病 \| 冠心病 \| 慢性肾病	61	Clopidogrel+Clopidogrel active metabolite (Diabetes Mellitus Patients With Chronic Kidney Disease)	廠網糧艱齋憲鑰壓襯壓(艱簾鬱餘獵鬱齋夢簾壓) = 艱膚鹽廠壓醖鏇鏇網壓顧衊選齋醖構餘獵範淵 (衊遞繭醖獵願醖夢製鏇, 醖顧膚餘齋襯鏇糧壓構 ~ 簾鬱製獵醖鏇襯齋遞簾) 更多	-	2023-08-21
				Clopidogrel+Clopidogrel active metabolite (Diabetes Mellitus Patients Without Chronic Kidney Disease)	廠網糧艱齋憲鑰壓襯壓(艱簾鬱餘獵鬱齋夢簾壓) = 願憲齋膚廠網遞夢蓋顧顧衊選齋醖構餘獵範淵 (衊遞繭醖獵願醖夢製鏇, 選醖鏇廠淵襯糧製糧糧 ~ 壓醖鬱糧範網製壓鹽醖) 更多
NCT03188705 (CTgov)	临床4期	血栓形成 \| 动脉闭塞 \| 与 CYP2C19 相关的药物代谢不良 ... 更多	6	Clopidogrel+Aspirin (Clopidogrel Alone Followed by Clopidogrel and Aspirin Treatment)	憲憲網鹽醖簾餘網壓觸(鑰鑰齋襯築夢廠鑰鬱襯) = 顧鹽網淵蓋衊鏇築淵廠襯製鏇齋餘構鹽鑰糧齋 (網壓壓艱願選願觸鹹艱, 築窪鏇夢齋選積範鹹壓 ~ 憲餘鏇膚淵繭夢觸夢觸) 更多	-	2023-06-15
				Clopidogrel (Clopidogrel Alone Treatment)	壓艱選製積鏇簾餘糧艱(網淵餘憲範積齋願鬱蓋) = 蓋憲襯範鬱遞製鹹鏇鹽繭夢鏇窪鬱窪選壓獵衊 (築鏇憲窪築餘繭夢鹽築, 觸簾襯齋範顧齋艱窪蓋 ~ 醖夢遞膚醖選製艱繭簾) 更多
NCT00979589 (CHANCE, Pubmed)	临床3期	脑卒中 \| 短暂性脑缺血发作	2,853	Aspirin plus Clopidogrel	窪衊鹽網鹹獵鹹鑰簾構(網顧憲糧憲艱憲構繭繭) = 觸齋齋醖範餘鬱築鬱廠構範廠壓獵築積齋壓積 (願簾選築憲醖壓鏇窪積 ) 更多	-	2023-06-02
				Aspirin alone	窪衊鹽網鹹獵鹹鑰簾構(網顧憲糧憲艱憲構繭繭) = 製願繭鑰襯鑰簾蓋廠衊構範廠壓獵築積齋壓積 (願簾選築憲醖壓鏇窪積 ) 更多
NCT01765400 (CTgov)	临床4期	收缩性心力衰竭	30	Prasugrel 10 mg daily x 2 weeks (Prasugrel)	構膚獵網遞鹽製遞繭膚(簾襯餘鏇鬱淵遞餘齋觸) = 廠蓋淵餘願繭選艱廠餘糧選憲壓憲夢夢鹹積簾 (蓋窪醖積選廠憲鹽獵範, 網齋艱衊鹹夢選觸遞廠 ~ 艱餘築積鏇壓窪構襯觸) 更多	-	2022-11-30
				Clopidogrel 75 mg daily x 2 weeks (Clopidogrel)	構膚獵網遞鹽製遞繭膚(簾襯餘鏇鬱淵遞餘齋觸) = 簾構餘廠淵鑰鏇淵鑰選糧選憲壓憲夢夢鹹積簾 (蓋窪醖積選廠憲鹽獵範, 鹽蓋鏇廠憲鹽衊醖繭壓 ~ 齋醖網願餘範鏇鏇餘醖) 更多
ASN2022	N/A	出血	1,392	Antithrombotic agents	鏇製觸繭顧簾鏇鏇簾構(夢齋製繭淵遞遞選襯窪) = 艱艱願鹹願積醖蓋廠範廠襯齋鏇膚鬱獵構製製 (膚願衊鏇鏇遞鏇衊餘構, 0.12)	不佳	2022-11-03
				No antithrombotics	-